Article Text

Download PDFPDF
Commentary
Commentary on Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank
  1. Pål Møller1,
  2. Toni T Seppälä2,3,
  3. Mev Dominguez-Valentin4,
  4. Julian Sampson5
  1. 1Department of Tumour Biology, Institute of Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
  2. 2Tampere University Hospital, Tampere, Finland
  3. 3University of Helsinki, Helsinki, Finland
  4. 4Department of Tumour Biology, The Norwegian Radium Hospital, Oslo, Norway
  5. 5Institute of Medical Genetics, Cardiff, UK
  1. Correspondence to Dr Pål Møller; moller.pal{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In their recent article, Fummey et al1 reported incidences of colorectal cancer (CRC) and other cancers in carriers of pathogenic mismatch repair (path_MMR) variants in a UK Biobank. Although cancer risks with smaller CIs have been determined previously in larger numbers of carriers using the Prospective Lynch Syndrome Database (PLSD),2 the findings from the UK Biobank are important as PLSD is likely to be subject to ascertainment biases given that participants are recruited on the basis of diagnostic or predictive genetic test results. By contrast, carriers in the UK Biobank were identified incidentally during …

View Full Text

Footnotes

  • Correction notice This article has been corrected since it was published online, to fix the spelling of two of the authors' last names.

  • Contributors First author guarantee that all authors have substantially contributed to and approved submission of the comment.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests TTS reports consultation fees from Tillotts Pharma, Nouscom and Mehiläinen, being a co-owner and CEO of Healthfund Finland Ltd, and a position in the Clinical Advisory Board and a minor shareholder of Lynsight Ltd.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles